Neurelis
CompanyUnited StatesFounded 2007
Neurelis develops 2 assets, the furthest approved (Valtoco in epilepsy). Mostly small molecule acting on GABRA5, GABRA1 and GABRG2; based in the United States, founded in 2007.
- 2
- Assets
- Furthest stage
- Approved
- 4
- Trials
- 4
- Signals
Pipeline
2Inhibits ROCK2 to stabilize vascular endothelial barriers and reduce vascular leakage.
Phase 1, Small molecule, ROCK2, cerebral cavernous malformations
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms12
- Trials5
- Signals4
- Similar companies6